MY109943A - Thienobenzodiazepine derivatives for treatment of cns disorders - Google Patents

Thienobenzodiazepine derivatives for treatment of cns disorders

Info

Publication number
MY109943A
MY109943A MYPI93001036A MYPI19931036A MY109943A MY 109943 A MY109943 A MY 109943A MY PI93001036 A MYPI93001036 A MY PI93001036A MY PI19931036 A MYPI19931036 A MY PI19931036A MY 109943 A MY109943 A MY 109943A
Authority
MY
Malaysia
Prior art keywords
treatment
cns disorders
alkyl
optionally substituted
thienobenzodiazepine
Prior art date
Application number
MYPI93001036A
Other languages
English (en)
Inventor
Fairhurst John
Michael Hotten Terrence
Edward Tupper David
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211379A external-priority patent/GB9211379D0/en
Priority claimed from GB939309025A external-priority patent/GB9309025D0/en
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of MY109943A publication Critical patent/MY109943A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MYPI93001036A 1992-05-29 1993-05-28 Thienobenzodiazepine derivatives for treatment of cns disorders MY109943A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211379A GB9211379D0 (en) 1992-05-29 1992-05-29 Pharmaceutical compounds
GB939309025A GB9309025D0 (en) 1993-04-30 1993-04-30 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
MY109943A true MY109943A (en) 1997-10-31

Family

ID=26300951

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI93001036A MY109943A (en) 1992-05-29 1993-05-28 Thienobenzodiazepine derivatives for treatment of cns disorders

Country Status (21)

Country Link
EP (1) EP0582368B1 (Direct)
JP (1) JP3219541B2 (Direct)
CN (1) CN1043994C (Direct)
AT (1) ATE198891T1 (Direct)
AU (1) AU668159B2 (Direct)
CA (1) CA2097016A1 (Direct)
CZ (1) CZ282783B6 (Direct)
DE (1) DE69329887T2 (Direct)
DK (1) DK0582368T3 (Direct)
ES (1) ES2153373T3 (Direct)
FI (1) FI101538B (Direct)
GR (1) GR3035587T3 (Direct)
HU (1) HU218278B (Direct)
IL (1) IL105827A (Direct)
MX (1) MX9303124A (Direct)
MY (1) MY109943A (Direct)
NO (1) NO305125B1 (Direct)
NZ (1) NZ247703A (Direct)
PT (1) PT582368E (Direct)
RU (1) RU2125574C1 (Direct)
TW (1) TW268005B (Direct)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
CN1219878A (zh) * 1996-03-25 1999-06-16 伊莱利利公司 治疗疼痛的方法
CZ298398A3 (cs) * 1996-03-25 1999-06-16 Eli Lilly And Company Farmaceutický přípravek
EP0921802A4 (en) * 1996-03-25 2002-05-08 Lilly Co Eli METHODS FOR TREATING PAIN
NZ334346A (en) * 1996-09-23 2000-05-26 Lilly Co Eli Olanzapine dihydrate D comprising 2-methyl-4-(4-methyl-1-piperazinyl)-1OH-thieno[2,3-b][1,5]benzodiazepine and a formulation for use in treating central nervous system disorders
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
PL332503A1 (en) * 1996-09-24 1999-09-13 Lilly Co Eli Coated particles containing preparation
RU2185383C1 (ru) * 2001-05-22 2002-07-20 Институт молекулярной генетики РАН ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ 2-МЕТИЛ-4-(4-МЕТИЛ-1-ПИПЕРАЗИНИЛ)-10Н-ТИЕНО[2,3-b][1,5]БЕНЗОДИАЗЕПИН
AU2013305970B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to aripiprazole haptens and use thereof
EP3462173B1 (en) 2012-08-21 2021-03-31 Janssen Pharmaceutica NV Antibodies to risperidone and use thereof
EP3663317B1 (en) 2012-08-21 2022-10-12 Janssen Pharmaceutica NV Antibodies to quetiapine haptens and use thereof
CA2882596C (en) 2012-08-21 2019-05-14 Ortho-Clinical Diagnostics, Inc. Antibodies to olanzapine and use thereof
AU2013305965B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Antibodies to paliperidone and use thereof
WO2014031601A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of risperidone and paliperidone
AU2013305935B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Haptens of quetiapine for use in immunoassays
WO2014031645A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to risperidone haptens and use thereof
ES2654413T3 (es) 2012-08-21 2018-02-13 Janssen Pharmaceutica, N.V. Anticuerpos a quetiapina y uso de los mismos
CA2882489A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone haptens and use thereof
EP3556759B1 (en) 2012-08-21 2023-11-29 Janssen Pharmaceutica NV Haptens of paliperidone
PL3321254T3 (pl) 2012-08-21 2021-01-11 Janssen Pharmaceutica Nv Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
EP3581195B1 (en) 2012-08-21 2025-10-01 Janssen Pharmaceutica NV Antibodies to olanzapine haptens and use thereof
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
ES2701062T3 (es) * 2012-08-21 2019-02-20 Janssen Pharmaceutica Nv Haptenos de olanzapina
CA3008809A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
EP3390455A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
CH569731A5 (Direct) * 1972-04-04 1975-11-28 Wander Ag Dr A
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
US4061752A (en) * 1975-08-06 1977-12-06 Sandoz Ltd. 6-Piperazino-11-methylene-dibenzazepines[b,e]
SE7610219L (sv) * 1975-09-24 1977-03-25 Sandoz Ag Nya dibenso /b,e//1,4/ diazepiner
CH624682A5 (Direct) * 1976-11-10 1981-08-14 Sandoz Ag
US4761411A (en) * 1983-05-18 1988-08-02 Hoechst-Roussel Pharmaceuticals Inc. Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
FI932445L (fi) 1993-11-30
DE69329887T2 (de) 2001-05-23
HU218278B (en) 2000-07-28
NO931917L (no) 1993-11-30
JP3219541B2 (ja) 2001-10-15
ES2153373T3 (es) 2001-03-01
CN1085903A (zh) 1994-04-27
CZ102493A3 (en) 1993-12-15
FI101538B1 (fi) 1998-07-15
IL105827A (en) 1997-02-18
DE69329887D1 (de) 2001-03-01
PT582368E (pt) 2001-05-31
DK0582368T3 (da) 2001-02-05
EP0582368B1 (en) 2001-01-24
HUT66180A (en) 1994-09-28
HU9301579D0 (en) 1993-09-28
IL105827A0 (en) 1993-09-22
ATE198891T1 (de) 2001-02-15
FI101538B (fi) 1998-07-15
CA2097016A1 (en) 1993-11-30
NO931917D0 (no) 1993-05-26
CZ282783B6 (cs) 1997-10-15
CN1043994C (zh) 1999-07-07
NZ247703A (en) 1995-07-26
AU3980793A (en) 1993-12-02
JPH0687862A (ja) 1994-03-29
NO305125B1 (no) 1999-04-06
FI932445A0 (fi) 1993-05-28
GR3035587T3 (en) 2001-06-29
TW268005B (Direct) 1996-01-11
RU2125574C1 (ru) 1999-01-27
MX9303124A (es) 1993-11-01
EP0582368A1 (en) 1994-02-09
AU668159B2 (en) 1996-04-26

Similar Documents

Publication Publication Date Title
MY109943A (en) Thienobenzodiazepine derivatives for treatment of cns disorders
IL65501A (en) 1-alkyl-2-aminotetralin derivatives,process for their preparation and pharmaceutical compositions containing them
MY113733A (en) Salts of an anti-migraine indole derivative
IL100572A (en) Amides of antibiotic ge 2270 factors their preparation and pharmaceutical compositions containing them
PH25859A (en) Composition for treatment of ischemic disorder
UA35609C2 (uk) Гетероцикліл-бензоїл-гуанідини, спосіб їх одержання (варіанти) і фармацевтична композиція, яка має здатність інгібувати целюлярний na+/h+-антиносій
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
AP9300561A0 (en) Antibiotic compounds.
GR3023934T3 (en) New naphthalene amides and sulfonamides, process for their preparation and pharmaceutical compositions containing them
ES8601915A1 (es) Un procedimiento para preparar derivados de piridazinona
HU9303000D0 (en) Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof
HUT64309A (en) Process for production pharmaceutical preparations having benzazepine compounds as effective substance and the new effective substance
GB8903036D0 (en) Chemical compounds
BG101929A (en) Benzamides for neurodegenerative disorder treatment
TW275629B (Direct)
IL122537A0 (en) Arylalkoxyphenoxy-imidazoline compounds process for their preparation and pharmaceutical compositions containing them
IL109227A0 (en) Leustroducsin h, pharmaceutical composition containing the same, and processes for the preparation thereof